Cambridge microbiome startup's shares sliced in half after key trial failure
Microbiome startup Seres Therapeutics' shares are in a free fall after the company announced that its ulcerative colitis drug had failed in a mid-stage clinical trial.
Seres (Nasdaq: MCRB) had been developing the drug in partnership with Nestlé Health Science as part of its suite of bacteria-based drugs, several of which are in clinical development. The ulcerative colitis study will be shut down, as the drug resulted in "no meaningful clinical differences" in a placebo comparison trial involving…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Rowan Walrath Source Type: news
More News: Clinical Trials | Health Management | Inflammatory Bowel Disease | Partnerships | Science | Study | Ulcerative Colitis